These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15655266)

  • 1. The effect of tirofiban on ST segment resolution in patients with non-ST elevated myocardial infarction.
    Bayturan O; Bilge AR; Seküri C; Utük O; Tikiz H; Eser E; Tezcan UK
    Jpn Heart J; 2004 Nov; 45(6):913-20. PubMed ID: 15655266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
    Uyarel H; Uzunlar B; Unal Dayi S; Tartan Z; Samur H; Kasikcioglu H; Akgul O; Simsek D; Erdem I; Okmen E; Cam N
    Cardiology; 2006; 105(3):168-75. PubMed ID: 16479104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
    JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
    N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
    J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
    Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
    Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ; Théroux P; Snapinn SM; Sax FL
    Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing outcomes in ST-segment elevation myocardial infarction.
    Herrmann HC
    J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574
    [No Abstract]   [Full Text] [Related]  

  • 18. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
    Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.
    Cutlip DE; Ricciardi MJ; Ling FS; Carrozza JP; Dua V; Garringer J; Giri S; Caputo RP
    Am J Cardiol; 2003 Oct; 92(8):977-80. PubMed ID: 14556878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI.
    Kaymaz C; Keleş N; Özdemir N; Tanboğa İH; Demircan HC; Can MM; Koca F; İzgi İA; Özkan A; Türkmen M; Kırma C; Esen AM
    Anatol J Cardiol; 2015 Nov; 15(11):899-906. PubMed ID: 25868037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.